Publications by authors named "L Q Ai"

Objectives: To investigate the effect of high glucose on macrophage polarization and the role of immune-responsive gene 1 (IRG1) in mediating its effect.

Methods: RAW264.7 cells were transfected with IRG1-overexpressing plasmid or IRG1 siRNA via electroporation and cultured in either normal or high glucose for 72 h to observe the changes in cell viability and morphology using CCK-8 assay and phase contrast microscopy.

View Article and Find Full Text PDF

Defect engineering is considered one of the most powerful strategies for regulating the catalytic activity of electrocatalysts. A deep understanding of the defect-involved mechanism in electrocatalytic process is of great importance but remains a challenging task. In this study, an anionic Se-vacancy (V) was introduced into iron diselenide (FeSe) nanoarrays, enabling the catalyst to exhibit improved electrocatalytic performance for sulfion oxidation reaction (SOR).

View Article and Find Full Text PDF
Article Synopsis
  • Researchers have developed targeted covalent nanodrugs that improve the delivery and effectiveness of small-molecule chemotherapeutics, overcoming challenges in drug accumulation in tumors.
  • The nanodrugs utilize near-infrared (NIR) irradiation to activate and bind to specific cancer cell receptors, significantly increasing the accumulation of the drug doxorubicin within tumors compared to standard methods.
  • These advancements lead to enhanced cancer treatment outcomes, boosting the immune response and reducing tumor size while also minimizing side effects compared to traditional treatments.
View Article and Find Full Text PDF

The developmental competence and epigenetic progression of oocytes gradually become dysregulated with increasing maternal age. However, the mechanisms underlying age-related epigenetic regulation in oocytes remain poorly understood. Zygote arrest proteins 1 and 2 (ZAR1/2) are two maternal factors with partially redundant roles in maintaining oocyte quality, mainly known by regulating mRNA stability.

View Article and Find Full Text PDF

Background: Pembrolizumab with/without platinum + 5-FU is approved for the first-line (1L) treatment of R/M HNSCC, and its monotherapy use requires PD-L1 Combined Positive Score (CPS) ≥ 1. We aimed to understand PD-L1 testing patterns and associations with patient characteristics and treatment choice in R/M HNSCC.

Methods: Adults with R/M HNSCC initiating 1L systemic therapy were included from a U.

View Article and Find Full Text PDF